Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fiblyzyme
- Development stage
- Phase 4
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Fiblyzyme is an investigational pharmaceutical drug being developed for the treatment of acute ischemic stroke. It is a fibrinolytic enzyme, meaning it functions by breaking down fibrin clots that obstruct blood flow in ischemic stroke. The drug is administered via intravenous drip. It is currently undergoing a multi-center, randomized, blind, placebo-controlled clinical trial by West China Hospital, Sichuan University and Beijing Saisheng Pharmaceutical Co., Ltd.
02
Targets
Fibrin (Factor Ia)
Beyond the preview
Go deeper on Fiblyzyme.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fiblyzyme.